

PTO/SB/08A(10-01)

Approved for use through 10/31/2012. OMB 051-0011  
US Patent & Trademark Office 1500 Jefferson Avenue, Suite 1200, Alexandria, VA 22304-6100

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/048,072
<b>Filing Date</b>	January 25, 2002
<b>First Named Inventor</b>	Franchini, Genoveffa
<b>Group Art Unit</b>	1648
<b>Examiner Name</b>	Parkin, Jeffrey

Sheet 1 of 2

Attorney Docket No: 1662.018US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-0108702A3	02/08/2001	Franchini, Genoveffa, et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 04-28-05", 3 pgs	
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 09-03-07", 5 pgs	
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Response filed 10-11-05 to Office Action mailed 04-28-05", 9 pgs	
		"International Application Serial No. PCT/US00/20641 (Atty Ref 1662.018EP1), International Preliminary Examination Report mailed 11-28-01", 5 pgs	
		AUTRAN, B. , et al., "Therapeutic vaccines for chronic infections", <u>Science</u> , 305(5681), (July 9, 2004),205-8	
		DORRELL, L. , et al., "Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine", <u>J Virol.</u> , 80(10), (May, 2006),4705-16	
		JOHN, M. , et al., "Control of HIV Replication by Cytotoxic T-Lymphocyte responses", <u>Journal of HIV Therapy</u> , 4(4), (1999),91-97	
		KINLOCH-DE LOES, S. , et al., "pact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.", <u>J Infect Dis.</u> , 192(4), (Aug. 15, 2005),607-17	
		MWAU, M. , et al., "A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans", <u>J Gen Virol.</u> , 85(Pt 4), (Apr., 2004),911-9	
		PAOLETTI, E. , et al., "Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC", <u>Dev Biol Stand.</u> , 84, (1995),159-163	
		PIALOUX, G. , et al., "A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA", <u>AIDS Res Hum Retroviruses.</u> , 11(3), (1995),373-381	
		ROSENWIRTH, B. , et al., "An anti-HIV strategy combining chemotherapy and therapeutic vaccination", <u>J Med Primatol.</u> , 28(4-5), (1999),195-205	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

03/31/2008

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to PTO.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/DRA(10-01)

Approved for use through 10/31/2012. CMB 601-1001

US Patent &amp; Trademark Office 1515 Constitution Avenue, N.E. Washington, D.C. 20548-0001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/048,072
<b>Filing Date</b>	January 25, 2002
<b>First Named Inventor</b>	Franchini, Genoveffa
<b>Group Art Unit</b>	1648
<b>Examiner Name</b>	Parkin, Jeffrey

Sheet 2 of 2

Attorney Docket No: 1662.018US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		TUBIANA, R. , et al., "Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).", <u>Vaccine</u> , 23(34), (July 29, 2005),4292-301	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

03/31/2008

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./**